Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-07 5:59 pm Purchase | 2026-03-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | RA Capital Management, L.P. | 7,626,705 6.300% | 7,626,705 (New Position) | Filing History |
| 2026-03-26 3:06 pm Sale | 2026-03-13 | 13G | ACLARIS THERAPEUTICS INC ACRS | VANGUARD GROUP INC | 0 0.000% | -6,662,063 (Position Closed) | Filing History |
| 2026-03-17 4:16 pm Purchase | 2026-03-09 | 13G | ACLARIS THERAPEUTICS INC ACRS | Deep Track Capital LP | 9,345,000 7.000% | 9,345,000 (New Position) | Filing History |
| 2026-02-09 1:42 pm Unchanged | 2025-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 14,250,000 11.900% | 0 (Unchanged) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | BlackRock Inc. BLK | 6,700,629 6.200% | 1,228,918 (+22.46%) | Filing History |
| 2026-01-09 08:59 am Purchase | 2025-12-09 | 13G | ACLARIS THERAPEUTICS INC ACRS | Biosion, Inc. | 11,281,950 9.400% | 11,281,950 (New Position) | Filing History |
| 2025-11-13 09:05 am Sale | 2025-09-30 | 13G | ACLARIS THERAPEUTICS INC ACRS | Adage Capital Management, L.P. | 5,278,144 4.870% | -2,923,200 (-35.64%) | Filing History |
| 2025-07-29 11:22 am Purchase | 2025-06-30 | 13G | ACLARIS THERAPEUTICS INC ACRS | VANGUARD GROUP INC | 6,662,063 6.150% | 1,691,809 (+34.04%) | Filing History |
| 2025-07-24 4:21 pm Sale | 2025-06-30 | 13G | ACLARIS THERAPEUTICS INC ACRS | Millennium Management LLC | 3,837,380 3.500% | -1,705,758 (-30.77%) | Filing History |
| 2025-07-17 7:44 pm Purchase | 2025-06-30 | 13G | ACLARIS THERAPEUTICS INC ACRS | BlackRock Inc. BLK | 5,471,711 5.100% | 3,439,247 (+169.22%) | Filing History |
| 2025-05-15 10:45 am Sale | 2025-03-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | Rock Springs Capital Management LP | 5,046,309 4.700% | -1,715,552 (-25.37%) | Filing History |
| 2025-05-12 09:07 am Sale | 2025-03-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | Adage Capital Management, L.P. | 8,201,344 7.600% | -1,425,960 (-14.81%) | Filing History |
| 2025-05-05 4:00 pm Purchase | 2025-04-28 | 13G | ACLARIS THERAPEUTICS INC ACRS | Millennium Management LLC | 5,543,138 5.100% | 2,537,540 (+84.43%) | Filing History |
| 2025-04-30 10:53 am Purchase | 2025-03-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | VANGUARD GROUP INC | 4,970,254 4.600% | 248,367 (+5.26%) | Filing History |
| 2025-02-13 2:26 pm Purchase | 2024-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 14,250,000 13.300% | 4,854,066 (+51.66%) | Filing History |
| 2025-02-12 09:31 am Purchase | 2024-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | Adage Capital Management, L.P. | 9,627,304 9.000% | 9,627,304 (New Position) | Filing History |
| 2024-11-25 11:02 am Purchase | 2024-11-18 | 13G | ACLARIS THERAPEUTICS INC ACRS | Biosion Inc. | 11,281,985 9.500% | 11,281,985 (New Position) | Filing History |
| 2024-11-22 4:00 pm Purchase | 2024-11-18 | 13G | ACLARIS THERAPEUTICS INC ACRS | Rock Springs Capital Management LP | 6,761,861 6.320% | 3,763,366 (+125.51%) | Filing History |
| 2024-11-21 4:51 pm Purchase | 2024-11-19 | 13G | ACLARIS THERAPEUTICS INC ACRS | Vivo Opportunity Fund Holdings, L.P. | 7,955,160 7.400% | 7,955,160 (New Position) | Filing History |
| 2024-11-14 4:14 pm Sale | 2024-09-30 | 13G | ACLARIS THERAPEUTICS INC ACRS | Citadel Advisors LLC | 368,067 0.500% | -5,038,022 (-93.19%) | Filing History |